Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Malignant Solid Neoplasm Clinical Trial

Official title:

Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04060849
• Other study ID #: RG1004525
• Secondary ID: NCI-2019-0515910
• Status: Suspended
• Phase: Phase 1
• Start date: September 3, 2019
• Est. completion date: July 2026

Study information

• Verified date: May 2024
• Source: Fred Hutchinson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic, alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and may also prevent community acquired respiratory virus infection in stem cell transplant recipients.

Description:

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose two times daily (BID) up to 100 days after transplant.

ARM II: Patients receive standard of care.

After completion of study, patients are followed up every week for 6 weeks and then every alternate week until day 100.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 50
• Est. completion date: July 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease

• English speaking

• Capable of providing informed consent

• Planned to receive follow-up at the transplant site for the first 100 days post transplantation

• Subjects who the investigator believes can and will comply with the study protocol

Exclusion Criteria:

• Documented respiratory viral infection in the two weeks prior to enrollment

• Current or planned use of any prophylactic antiviral therapy, antibody treatments, or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir, ribavirin, amantadine)

• Known allergy to study drug components (jojoba, orange oil, coconut oil, lauric acid, benzalkonium chloride, vitamin E)

• Receiving oxygen supplementation at time of enrollment

• Active mucositis at time of enrollment

• Ongoing irritation or active infection of the squamous epithelial cell skin involving the nose or nasal vestibule

• Daily use of nasal decontamination products or other nasal medications (e.g. nasal steroids)

• Unable to complete study procedures (e.g. nasal swab self-testing)

Related Conditions & MeSH terms

• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Neoplasms
• Solid Neoplasm

Intervention

Drug:
• Nozin
Given via nasal single-use popswabs or single-use cotton tipped applicators

Other:
• Best Practice
Receive standard of care

Locations

Country	Name	City	State
United States	University of Chicago Medicine-Orland Park	Orland Park	Illinois
United States	Fred Hutch/University of Washington Cancer Consortium	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Fred Hutchinson Cancer Center	Global Life Technologies Corp.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerability of Nozin	Will measure and describe reasons for dropout, defined as failure to complete the study to day 100 for any reason. Among participants in the study product arm, reasons for dropout will be classified as either directly related to the product or due to other reasons. Will estimate the proportion of participants who exit the study for reasons directly related to the study product with a precision of +/- 20% (95% confidence interval) to inform tolerability of study product for future studies. Will compare dropout for any reason between treatment arms using Fisher's exact test.	Up to 100 days post-transplant
Primary	Incidence of adverse events (AEs)	AEs will be graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All adverse events will be continually monitored by the study team and descriptively compared between study arms.	Up to 100 days post-transplant
Secondary	Incidence of community acquired respiratory viruses (CARV)	Will compare the cumulative incidence of CARV between study arms, counting death as a competing risk. Cox regression will be used to test for differences in the cause-specific hazard of CARV between study arms.	Up to 100 days post-transplant
Secondary	Frequency of respiratory viral symptoms	Will use Poisson generalized estimating equation regression models to compare the frequency of respiratory viral symptoms between study arms	Up to 100 days post-transplant
Secondary	Number of respiratory viral panel tests	Will compare the number of respiratory viral panel tests sent to the lab between study arms using Poisson regression with an offset for the number of days each participant was in the study.	Up to 100 days post-transplant